Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

被引：0
|
作者：
Alonso-Gordoa, T. [1 ]
Capdevila, J. [2 ]
Gonzalez, E. [3 ]
Teule, A. [4 ]
Anido, U. [5 ]
Segura, A. [6 ]
Bolanos, M. [7 ]
Hernando, J. [2 ]
Lorenzo, I [8 ]
Grandoulier, A. S. [9 ]
de La Cruz, G. [10 ]
机构：
[1] Hosp Univ Ramon y Cajal, Madrid, Spain
[2] Hosp Univ Vall dHebron, Barcelona, Spain
[3] Hosp Univ Virgen de las Nieves, Granada, Spain
[4] Hosp ICO Bellvitge, Barcelona, Spain
[5] Hosp Prov Conxo, Santiago De Compostela, Spain
[6] Hosp Univ & Politecn La Fe, Valencia, Spain
[7] Hosp Univ Juan Ramon Jimenez, Huelva, Spain
[8] Hosp Alvaro Cunqueiro, Vigo, Spain
[9] Ipsen Pharma, Boulogne, France
[10] Ipsen Pharma, Barcelona, Spain
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
net; pancreas; lanreotide; clinical practice;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I02
引用
收藏
页码：164 / 164
页数：1
相关论文
共 25 条
  • [1] Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study
    Pavel, M.
    Cwikla, J.
    Lombard-Bohas, C.
    Borbath, I.
    Shah, T.
    Pape, U. -F.
    Thanh, X. -M. Truong
    Houchard, A.
    Ruszniewski, P.
    PANCREAS, 2021, 50 (03) : 448 - 448
  • [2] CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen
    Ruszniewski, Philippe
    Cwikla, Jaroslaw
    Lombard-Bohas, Catherine
    Borbath, Ivan
    Shah, Tahir
    Pape, Ulrich -Frank
    Xuan-Mai Truong Thanh
    Houchard, Aude
    Pavel, Marianne
    PANCREAS, 2020, 49 (03) : 484 - 485
  • [3] Safety and efficacy of lanreotide autogel/depot (LAN) every 14 days for patients with pancreatic or midgut neuroendocrine tumours (NETs) progressing on LAN every 28 days: The prospective, international CLARINET FORTE study
    Pavel, M.
    Dromain, C.
    Massien, C.
    Houchard, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results
    Pavel, M.
    Cwikla, J. B.
    Lombard-Bohas, C.
    Borbath, I
    Shah, T.
    Pape, U. F.
    Thanh, Truong X. M.
    Houchard, A.
    Ruszniewski, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 143 - 143
  • [5] Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results
    Pavel, M.
    Cwikla, J. B.
    Lombard-Bohas, C.
    Borbath, I.
    Shah, T.
    Pape, U-F.
    Thanh, X-M. Truong
    Houchard, A.
    Ruszniewski, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S773 - S773
  • [6] Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen
    Ruszniewski, P.
    Cwikla, J.
    Lombard-Bohas, C.
    Borbath, I.
    Shah, T.
    Pape, U-F.
    Thanh, X-M. Truong
    Houchard, A.
    Pavel, M. E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] CLARINET FORTE: Characterization of Pharmacokinetics (PK), efficacy and safety in patients with progressive neuroendocrine tumors (NETs) treated with Lanreotide Autogel (LAN) 120 mg every 14 days (q14d)
    Dehez, M.
    Brendel, K.
    Sarr, C.
    Bjornsson, M.
    Thanh, Truong X. M.
    Pavel, M.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 133 - 133
  • [8] Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria
    Rinke, Anja
    Maintz, Christoph
    Mueller, Lothar
    Weber, Matthias M.
    Lahner, Harald
    Pavel, Marianne
    Saeger, Wolfgang
    Houchard, Aude
    Ungewiss, Hanna
    Petersenn, Stephan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2021, 129 (07) : 500 - 509
  • [9] Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days
    Bronstein, M
    Musolino, N
    Jallad, R
    Cendros, JM
    Ramis, J
    Obach, R
    Leselbaum, A
    Catus, F
    CLINICAL ENDOCRINOLOGY, 2005, 63 (05) : 514 - 519
  • [10] Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/ Depot (LAN) for Patients with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
    Pavel, M.
    Dromain, C.
    Majdi, A.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2017, 105 : 204 - 204
123